Core Viewpoint - 微创机器人-B (02252) announced the nomination of new non-executive and independent non-executive directors, alongside the resignation of several key board members due to personal commitments [1] Group 1: Board Nominations - The board has nominated Dr. Chang Zhaohua, Mr. Bai Tengtaisi, Mr. Lu Tianyu, and Ms. Liang Min as non-executive directors [1] - The board has also nominated Mr. Zhou Jiahong and Dr. Liu Guoen as independent non-executive directors [1] Group 2: Resignations - Mr. Sun Hongbin resigned from his positions as non-executive director, chairman of the board, and member of various committees due to the need to allocate more time to other duties, effective after the upcoming extraordinary general meeting [1] - Ms. Fang Cong resigned from her role as executive director and member of the nomination committee for similar reasons, effective after the upcoming extraordinary general meeting [1] - Dr. Li Minghua also resigned from his position as independent non-executive director and various committee memberships due to the need to allocate more time to other duties, effective after the upcoming extraordinary general meeting [1]

Core Viewpoint - The company announced significant changes in its board of directors, including the nomination of new non-executive and independent non-executive directors, as well as the resignation of several key members due to time commitments [1]. Group 1: Board Changes - The board has nominated Dr. Chang Zhaohua, Mr. Bai Tengtaisi, Mr. Lu Tianyu, and Ms. Liang Min as non-executive directors [1]. - Mr. Zhou Jiaohong and Dr. Liu Guoen have been nominated as independent non-executive directors [1]. - Mr. Sun Hongbin resigned from his positions as non-executive director, chairman of the board, and various committee roles due to the need to allocate more time to other duties, effective after the upcoming extraordinary general meeting [1]. - Ms. Fang Cong also resigned from her role as executive director and committee member for similar reasons, effective after the extraordinary general meeting [1]. - Dr. Li Minghua stepped down from his position as independent non-executive director and various committee roles, effective after the extraordinary general meeting, citing the need for more time for other commitments [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 董事變動 及 建議修訂組織章程細則及股東大會議事規則 董事變動 上海微創醫療機器人（集團）股份有限公司（「本公司」）董事會（「董事會」）謹此 宣佈董事會成員變動如下： 董事辭任 建議委任非執行董事 董事會決議提名常兆華博士（「常博士」）、白藤泰司先生（「白藤先生」）、蘆田典 裕先生（「蘆田先生」）、梁敏女士（「梁女士」）為本公司非執行董事。建議委任常 博士、白藤先生、蘆田先生、梁女士為本公司非執行董事須待本公司股東於臨 時股東大會上審議及批准。 常博士、白藤先生、蘆田先生及梁女士之履歷詳情載列如下： 常兆華博士 常兆華博士，62歲。常博士在醫療器械行業擁有逾34年的經驗，現時擔任微創 醫療科學有限公司（「 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 RMB | | 1 | RMB | | 6,599,543 | | 2. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 ...

港股机器人概念股午后集体冲高，三花智控涨超11%，微创机器人涨超8%，极智嘉、优必选涨超 5%，越疆涨近3%。 | 机器人概念股 | | | | --- | --- | --- | | 2735.372↑ +69.641 +2.61% | | 交易中 | | * 2 目 4 | | | | 最高价 2746.519 开盘价 2709.480 | 成交量 4.82亿 | | | 最低价 2674.221 昨收价 2665.731 | 成交额 212.29亿 | | | 市盈率 46.753 换手率 0.67% | | 总市值 3.58万亿 (m | | 市净率 3.898 平均价 2710.370 | 流通值 2.62万亿 | | | 上 涨 20 平 盘 0 | 下 跌 2 | | | 52周最高 3069.597 历史最高 3069.597 | | | | 52周最低 1227.336 历史最低 708.270 | | | | 1 | | | 个股消息上，三花智控近日斩获特斯拉Optimus机器人50亿大单。 摩根大通发布，微创机器人全球订单动力仍然强劲。基于图迈累计订单约100套，上调今年完成安 装数量预 ...

摩通上调对微创机器人目标价，由30.9港元上调至42港元，评级"增持"，重申该股为中国医疗科技股首 选，并指股价在基本因素未变下回调为良好的买入机会。 摩根大通发表研究报告指，微创机器人全球订单动力仍然强劲。基于Toumai(四臂腔镜手术机器人)累计 订单约100套，该行上调今年完成安装数量预测，由84套上调至105套，主要在海外增长及假设订单可在 少于一季内转化为销售入账。更高的安装量基础及产品组合改善，以及预期毛利率1至1.5个百分点改 善。 ...

Core Viewpoint - MicroPort Robotics-B (02252) has seen a significant increase in its stock price, with a rise of over 5% in early trading, reflecting strong market confidence following the announcement of robust order volumes for its core products [1] Group 1: Company Performance - The cumulative order volume for MicroPort Robotics' core products, including endoscopic, orthopedic, and vascular intervention devices, has surpassed 170 units [1] - The "TUMAI" endoscopic surgical robot has achieved over 100 commercial orders globally, with nearly 80 units installed, maintaining the leading position among domestic brands [1] - The company is entering a phase of accelerated commercialization, indicating strong growth potential in the market [1] Group 2: Market Analysis - JPMorgan has reported that the global order momentum for MicroPort Robotics remains strong, leading to an upward revision of the installation forecast for the year from 84 units to 105 units [1] - This adjustment is primarily driven by growth in overseas markets and the assumption that orders can be converted to sales within less than a quarter [1] - The expected improvement in installation volume and product mix is anticipated to enhance the gross margin by 1 to 1.5 percentage points [1] Group 3: Investment Outlook - Morgan Stanley has raised its target price for MicroPort Robotics from HKD 30.9 to HKD 42, maintaining an "Overweight" rating on the stock [1]

Core Viewpoint - MicroPort Scientific Corporation's stock price increased by over 5%, currently trading at 28.86 HKD, with a trading volume of 23.74 million HKD, following the announcement of significant order growth for its core products [1] Group 1: Company Performance - The cumulative order volume for MicroPort's core products, including endoscopic, orthopedic, and vascular intervention devices, has surpassed 170 units [1] - The "Tumi" endoscopic surgical robot has achieved over 100 commercial orders globally, with nearly 80 units installed, maintaining the leading position among domestic brands [1] Group 2: Market Outlook - JPMorgan reported that the global order momentum for MicroPort remains strong, raising the installation forecast for this year from 84 units to 105 units, driven by overseas growth and the assumption that orders can be converted to sales within a quarter [1] - The expected improvement in installation volume and product mix is anticipated to enhance gross margins by 1 to 1.5 percentage points [1] Group 3: Analyst Rating - JPMorgan has raised its target price for MicroPort from 30.9 HKD to 42 HKD, maintaining an "Overweight" rating [1]

Core Viewpoint - Morgan Stanley has raised the target price for MicroPort Scientific Corporation (02252) from HKD 30.9 to HKD 42, maintaining an "Overweight" rating and identifying the stock as a top choice in China's medical technology sector, indicating that the recent price pullback presents a good buying opportunity [1] Group 1: Company Performance - MicroPort's global order momentum remains strong, with over 170 surgical robot orders accumulated as of last Wednesday, up from 150 orders at the end of August [1] - The installation of the Toumai (four-arm laparoscopic surgical robot) is accelerating globally, with applications in nearly 40 countries and major hospital systems, driving strong adoption [1] Group 2: Financial Projections - Based on approximately 100 cumulative orders for Toumai, the company has revised its installation forecast for this year from 84 units to 105 units, primarily due to overseas growth and the assumption that orders can be converted to sales within less than a quarter [1] - An improved installation base and product mix, along with an expected gross margin improvement of 1 to 1.5 percentage points, are anticipated [1]

智通财经APP获悉，摩根大通发布研报称，上调对微创机器人-B(02252)目标价，由30.9港元上调至42港 元，此按现金流折现率作估值，投资评级"增持"，重申该股为中国医疗科技股首选，并指股价在基本因 素未变下回调为良好的买入机会。 微创机器人全球订单动力仍然强劲，截至上周三(8日)累计手术机器 人订单逾170套，高于8月底的150套。该行指，Toumai(四臂腔镜手术机器人)安装在全球加速，国际扩 张急速，在近40个国家及主要医院系统应用，推动强劲的采用。 该信息由智通财经网提供 该行基于Toumai累计订单约100套，上调今年完成安装数量预测，由84套上调至105套，主要在海外增 长及假设订单可在少于一季内转化为销售入账。 更高的安装量基础及产品组合改善，以及预期毛利率1 至1.5个百分点改善。 ...